NCE-1 Intelligence & Market Opportunity

Jesduvroq

Daprodustat

Antianemic

Tablet

Jesduvroq is an oral HIF-PHI approved for the treatment of anemia in adults with chronic kidney disease on dialysis. It was voluntarily withdrawn in the U.S. for non-safety-related reasons but remains FDA-listed.

Approval Date

01-Feb-23

NCE-1 Date

01-Feb-27

NCE Date

01-Feb-28

Commercial snapshot

Market performance & projections

Revenue ($M)

100

CAGR (%)

0.2368

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

174

2027

197

2028

221

2029

234

2030

236

2031

246

2032

258

Molecule profile

Details & specifications

Molecule

Daprodustat

Innovator

GLAXOSMITHKLINE INTELLECTUAL PROPERTY NO 2 LTD ENGLAND

Dosage Form

Tablet

Strength

1 mg, 2 mg, 4 mg, 6 mg, 8 mg

Therapeutic Category

Antianemic

Usage

To treat anemia caused by chronic kidney disease for adults on dialysis for at least four months

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.